AGP Executive Report
Last update: 9 hours agoSterile API Expansion: Curia is investing to expand sterile API manufacturing in Valladolid, Spain, targeting injectable suspensions and complex sterile formulations, with completion expected in Q4 2028. AI Medical Devices Regulation: The UK will implement all 44 recommendations from its AI-in-healthcare commission, including continuous monitoring of AI-enabled medical devices post-approval. Clinical Imaging & Devices: Riverain’s FDA-cleared ClearRead™ Chest AI suite is now available via RapidAI’s enterprise platform, while Penn Highlands Elk adds CT perfusion to broaden stroke treatment decision-making. Heart Failure Device Trial: BioVentrix completed first patient treatments in Georgia for its Revivent System in the pivotal RELIVE trial. Telehealth Scale-Up: India’s eSanjeevani platform surpassed 50 crore teleconsultations, with women making up 57% of visits. Rural Addiction Care Funding: Porch Light Health won $6.6M from Colorado’s Rural Health Transformation Program to expand coordinated addiction treatment. New CSF Molecular Tests: Cerenome’s CNSide launched CSF DNA/RNA profiling tests for CNS solid tumors and hematologic malignancies. Health System Collaboration: SCAN Health Plan and Sutter Health expand Medicare Advantage co-branded products into more Northern California counties starting in 2027. MedTech Investment Push: Malaysia’s Penang reported RM2.3B in approved MedTech investments (2021–Q1 2026), creating nearly 4,500 jobs.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
